Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus

NACompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Systemic Lupus Erythematosus
Interventions
OTHER

Drug free

Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.

DRUG

HCQ

Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d

DRUG

GC+HCQ

Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.

Trial Locations (5)

100730

Peking Union Medical College Hospital, Beijing

110004

Shengjing Hospital of China Medical University, Shenyang

230001

Anhui Provincial Hospital, Hefei

410008

Xiangya Hospital of Central South University, Changsha

830001

People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Shengjing Hospital

OTHER

collaborator

People's Hospital of Xinjiang Uygur Autonomous Region

OTHER

collaborator

Anhui Provincial Hospital

OTHER_GOV

collaborator

Beijing Hospital

OTHER_GOV

lead

Peking Union Medical College Hospital

OTHER

NCT02842814 - Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter